vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and HERITAGE COMMERCE CORP (HTBK). Click either name above to swap in a different company.

HERITAGE COMMERCE CORP is the larger business by last-quarter revenue ($53.6M vs $37.2M, roughly 1.4× GYRE THERAPEUTICS, INC.). HERITAGE COMMERCE CORP runs the higher net margin — 28.2% vs -3.7%, a 31.9% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 15.6%). HERITAGE COMMERCE CORP produced more free cash flow last quarter ($61.3M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 12.8%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

The United States Chamber of Commerce (USCC) is a business association advocacy group and is the largest lobbying group in the United States. The group was founded in April 23, 1912, out of local chambers of commerce at the urging of President William Howard Taft and his secretary of commerce and labor Charles Nagel. President Taft's belief was that the "government needed to deal with a group that could speak with authority for the interests of business."

GYRE vs HTBK — Head-to-Head

Bigger by revenue
HTBK
HTBK
1.4× larger
HTBK
$53.6M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+17.8% gap
GYRE
33.4%
15.6%
HTBK
Higher net margin
HTBK
HTBK
31.9% more per $
HTBK
28.2%
-3.7%
GYRE
More free cash flow
HTBK
HTBK
$67.1M more FCF
HTBK
$61.3M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
12.8%
HTBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
HTBK
HTBK
Revenue
$37.2M
$53.6M
Net Profit
$-1.4M
$15.1M
Gross Margin
95.3%
Operating Margin
0.3%
41.0%
Net Margin
-3.7%
28.2%
Revenue YoY
33.4%
15.6%
Net Profit YoY
-340.1%
42.3%
EPS (diluted)
$-0.01
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
HTBK
HTBK
Q4 25
$37.2M
$53.6M
Q3 25
$30.6M
$50.0M
Q2 25
$26.8M
$47.8M
Q1 25
$22.1M
$46.1M
Q4 24
$27.9M
$46.4M
Q3 24
$25.5M
$42.2M
Q2 24
$25.2M
$41.7M
Q1 24
$27.2M
$42.1M
Net Profit
GYRE
GYRE
HTBK
HTBK
Q4 25
$-1.4M
$15.1M
Q3 25
$5.9M
$14.7M
Q2 25
$1.6M
$6.4M
Q1 25
$3.7M
$11.6M
Q4 24
$569.0K
$10.6M
Q3 24
$2.9M
$10.5M
Q2 24
$4.5M
$9.2M
Q1 24
$9.9M
$10.2M
Gross Margin
GYRE
GYRE
HTBK
HTBK
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
HTBK
HTBK
Q4 25
0.3%
41.0%
Q3 25
22.7%
41.1%
Q2 25
8.1%
18.7%
Q1 25
10.3%
35.4%
Q4 24
2.4%
31.8%
Q3 24
16.6%
34.3%
Q2 24
12.7%
31.3%
Q1 24
29.7%
34.2%
Net Margin
GYRE
GYRE
HTBK
HTBK
Q4 25
-3.7%
28.2%
Q3 25
19.4%
29.4%
Q2 25
5.9%
13.4%
Q1 25
16.9%
25.2%
Q4 24
2.0%
22.9%
Q3 24
11.2%
24.9%
Q2 24
18.0%
22.1%
Q1 24
36.6%
24.1%
EPS (diluted)
GYRE
GYRE
HTBK
HTBK
Q4 25
$-0.01
$0.25
Q3 25
$0.03
$0.24
Q2 25
$0.00
$0.10
Q1 25
$0.00
$0.19
Q4 24
$0.00
$0.17
Q3 24
$0.01
$0.17
Q2 24
$0.01
$0.15
Q1 24
$0.03
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
HTBK
HTBK
Cash + ST InvestmentsLiquidity on hand
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$708.6M
Total Assets
$166.1M
$5.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
HTBK
HTBK
Q4 25
$52.4M
Q3 25
$60.0M
Q2 25
$54.4M
Q1 25
$29.9M
Q4 24
$26.7M
Q3 24
$25.1M
Q2 24
$25.1M
Q1 24
$37.4M
Stockholders' Equity
GYRE
GYRE
HTBK
HTBK
Q4 25
$106.0M
$708.6M
Q3 25
$101.9M
$700.0M
Q2 25
$92.0M
$694.7M
Q1 25
$68.1M
$696.2M
Q4 24
$63.3M
$689.7M
Q3 24
$63.2M
$685.4M
Q2 24
$60.4M
$679.2M
Q1 24
$56.6M
$676.3M
Total Assets
GYRE
GYRE
HTBK
HTBK
Q4 25
$166.1M
$5.8B
Q3 25
$159.4M
$5.6B
Q2 25
$152.6M
$5.5B
Q1 25
$129.8M
$5.5B
Q4 24
$125.4M
$5.6B
Q3 24
$125.2M
$5.6B
Q2 24
$120.9M
$5.3B
Q1 24
$122.0M
$5.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
HTBK
HTBK
Operating Cash FlowLast quarter
$-5.6M
$61.7M
Free Cash FlowOCF − Capex
$-5.8M
$61.3M
FCF MarginFCF / Revenue
-15.5%
114.3%
Capex IntensityCapex / Revenue
0.4%
0.7%
Cash ConversionOCF / Net Profit
4.08×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
HTBK
HTBK
Q4 25
$-5.6M
$61.7M
Q3 25
$4.7M
$18.9M
Q2 25
$2.1M
$8.0M
Q1 25
$-129.0K
$14.8M
Q4 24
$-2.8M
$39.0M
Q3 24
$1.7M
$5.3M
Q2 24
$-5.5M
$10.5M
Q1 24
$2.9M
$7.3M
Free Cash Flow
GYRE
GYRE
HTBK
HTBK
Q4 25
$-5.8M
$61.3M
Q3 25
$4.0M
$18.8M
Q2 25
$1.8M
Q1 25
$-251.0K
Q4 24
$-2.8M
$37.3M
Q3 24
$1.0M
$4.9M
Q2 24
$-6.9M
$9.9M
Q1 24
$2.7M
$6.9M
FCF Margin
GYRE
GYRE
HTBK
HTBK
Q4 25
-15.5%
114.3%
Q3 25
13.1%
37.7%
Q2 25
6.8%
Q1 25
-1.1%
Q4 24
-10.1%
80.5%
Q3 24
4.1%
11.6%
Q2 24
-27.5%
23.6%
Q1 24
9.8%
16.4%
Capex Intensity
GYRE
GYRE
HTBK
HTBK
Q4 25
0.4%
0.7%
Q3 25
2.2%
0.1%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
0.2%
3.5%
Q3 24
2.7%
1.0%
Q2 24
5.8%
1.6%
Q1 24
0.9%
1.0%
Cash Conversion
GYRE
GYRE
HTBK
HTBK
Q4 25
4.08×
Q3 25
0.79×
1.28×
Q2 25
1.32×
1.25×
Q1 25
-0.03×
1.28×
Q4 24
-4.85×
3.67×
Q3 24
0.60×
0.50×
Q2 24
-1.21×
1.14×
Q1 24
0.29×
0.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons